ArticleJCO precision oncology2021
Impact of ALK Inhibitors in Patients With
Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 29 citations in OpenAlex.
- Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.Blood cancer journal · 2026Article
- Durable response to ALK inhibition in low-allele-frequencyFrontiers in oncology · 2026Article
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives.Frontiers in immunology · 2026Review
- Anaplastic Lymphoma Kinase Positive Aggressive Adult Lung Primary Inflammatory Myofibroblastoma Tumor: A Case and Literature Review.Pharmacogenomics and personalized medicine · 2026Article
- Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.International journal of molecular sciences · 2025Review
- ALK-positive adult histiocytosis with a TFG-ALKfusion gene.The oncologist · 2025Article
- ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion.Cancer research and treatment · 2025Article
- Chinese Expert Consensus on the Diagnosis and Treatment of Inflammatory Myofibroblastic Tumor.Thoracic cancer · 2025Review
- Genetic profiling of osteosarcoma in an adolescent using a next‑generation sequencing panel and Sanger sequencing: A case report and review of the literature.Biomedical reports · 2025Article
- Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.The oncologist · 2025Article
- Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers.Nature communications · 2024Article
- ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models.iScience · 2024Article
- Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment.Oncology research · 2024Review
- Imaging features of ALK-positive histiocytosis with neurological involvement: a case report and literature review.Frontiers in oncology · 2024Article
- Update of Diagnosis and Targeted Therapy for ALKCurrent treatment options in oncology · 2023Review
- Sensitivity to ALK-Directed Therapy in Osteosarcoma With an AcquiredJCO precision oncology · 2023Article
- Anaplastic lymphoma kinase-positive inflammatory myofibroblastic tumor of the breast: a case report and review of the literature.Surgical case reports · 2023Article
- Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report.JTO clinical and research reports · 2023Article
- Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Role of CTNNA1 in Malignancies: An Updated Review.Journal of Cancer · 2023Review
Corrections and comments
- Commented on by
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAnaplastic lymphoma kinase ( PATIENTS AND
methodsBetween April 2012 and April 2019, clinical outcomes and characteristics of patients with
resultsWe identified seven patients (inflammatory myofibroblastic tumors, n = 3; ALK-positive histiocytosis, n = 1; histiocytic sarcoma, n = 1; osteosarcoma, n = 1; and parotid adenocarcinoma, n = 1), with a median age of 17 years. Two rare
conclusionThis study highlights the potential benefit of ALK-TKIs, especially alectinib, in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.